HOME > BUSINESS
BUSINESS
- Hisamitsu to Establish Subsidiary in Malaysia in October
January 14, 2020
- Eisai Cancer Drug Halaven Goes on Sale in China
January 14, 2020
- Kaken Files Axillary Hyperhidrosis Med in Japan
January 14, 2020
- Healios to Develop Next-Generation Cancer Immunotherapy
January 14, 2020
- Sumitomo Dainippon’s Altavant Picks Up Onspira
January 10, 2020
- Chugai Licenses KRAS-Targeting Drug to Verastem
January 10, 2020
- Keytruda Remains Top-Seller in December Drug Ranking in Japan: Encise
January 10, 2020
- Hisamitsu Starts 2 PIII Studies for NSAIDs Patch, Plans Filing by February 2022
January 10, 2020
- Bristol-Myers Japan Chief Doubles as Celgene President amid Transition
January 10, 2020
- US District Court Dismisses Asahi Kasei’s Request for Continuing Supply of Xiaflex
January 10, 2020
- Meiji Gains Japan Rights for Novel Blood Cancer Treatment from HUYA Bioscience
January 10, 2020
- Keytruda Top New Sales Generator in 2020, Enhertu Seen as Biggest Arrival: Evaluate
January 9, 2020
- Kyowa Kirin Seeks Add’l Indication for Lumicef
January 9, 2020
- Mitsubishi Chemical to Purchase 197 Million Shares of Mitsubishi Tanabe, Taking Over 90% Ownership
January 9, 2020
- ASKA Grabs Japan, South Korea Rights to Insud’s Oral Contraceptive
January 9, 2020
- Promethera Kicks Off PIIb Study of Cell-Based Therapy HepaStem for ACLF in Europe
January 9, 2020
- Chugai Chairman Pushes for Industry Shakeup, Govt Initiative to Develop Ecosystem
January 8, 2020
- Daiichi Sankyo’s Blockbuster Hopeful Enhertu Hits US Market
January 8, 2020
- Meiji Seika Forms JV with US Startup to Develop, Commercialize cGVHD Treatment
January 8, 2020
- Kyorin Grabs Japan Rights to aTyr’s Immunomodulator
January 7, 2020
ページ
Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…
